Laboratory of Biological Dosimetry, National Radiation Emergency Medical Center, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Republic of Korea.
Dongnam Radiation Emergency Medical Center, Dongnam Institute of Radiological and Medical Sciences, Busan 46033, Republic of Korea; Department of Radiation Oncology, Dongnam Institute of Radiological and Medical Sciences, Busan 46033, Republic of Korea.
Mutat Res Genet Toxicol Environ Mutagen. 2021 Dec;872:503419. doi: 10.1016/j.mrgentox.2021.503419. Epub 2021 Oct 20.
Although radiological accidents often result in partial-body radiation exposure, most biodosimetry studies focus on estimating whole-body exposure doses. We have evaluated time-dependent changes in chromosomal aberrations before, during, and after localized fractionated radiotherapy. Twelve patients with carcinoma in situ of the breast who underwent identical adjuvant radiation therapy (50 Gy in 25 fractions) were included in the study. Lymphocytes were collected from patients before, during, and after radiotherapy, to measure chromosome aberrations, such as dicentric chromosomes and translocations. Chromosome aberrations were then used to calculate whole- and partial-body biological absorbed doses of radiation. Dicentric chromosome frequencies in all study participants increased during radiotherapy (p < 0.05 in Kruskal-Wallis test). Increases of translocation frequencies during radiotherapy were observed in seven of the twelve patients. The increased levels of dicentric chromosomes and translocations persisted throughout our 1-year follow-up, and evidence of partial-body exposure (such as Papworth's U-value > 1.96) was observed more than 1 year after radiotherapy. We found that cytogenetic biomarkers reflected partial-body fractionated radiation exposure more than 1 year post-exposure. Our findings suggest that chromosome aberrations can be used to estimate biological absorbed radiation doses and can inform medical intervention for individuals suspected of fractionated or partial-body radiation exposure.
虽然放射事故通常导致局部身体辐射暴露,但大多数生物剂量学研究都集中在估计全身暴露剂量上。我们已经评估了局部分次放射治疗前后染色体畸变的时变变化。本研究纳入了 12 例接受相同辅助放疗(50Gy/25 次)的原位乳腺癌患者。在放疗前、放疗中和放疗后,从患者身上采集淋巴细胞,以测量染色体畸变,如双着丝粒染色体和易位。然后,利用染色体畸变来计算全身和局部的辐射生物吸收剂量。所有研究参与者的双着丝粒染色体频率在放疗期间增加(Kruskal-Wallis 检验,p<0.05)。在 12 例患者中,有 7 例在放疗期间观察到易位频率增加。双着丝粒染色体和易位的增加水平在我们 1 年的随访中持续存在,并且在放疗后 1 年以上观察到了局部暴露(如 Papworth 的 U 值>1.96)的证据。我们发现细胞遗传学生物标志物在暴露后 1 年以上能更好地反映局部分次辐射暴露。我们的研究结果表明,染色体畸变可用于估计生物吸收辐射剂量,并为疑似局部或分次辐射暴露的个体提供医学干预的依据。